The oral PCSK9 inhibitor enlicitide decanoate achieved 58% LDL-C reduction in patients with heterozygous familial hypercholesterolemia, offering a potential alternative to injectable therapies.
Researchers examine the strengths and shortcomings of the current European Alliance of Associations for Rheumatology definition for difficult-to-treat rheumatoid arthritis.